February 2026 Options Now Available For Arcus Biosciences (RCUS)

Arcus Biosciences (RCUS) is highlighted in a covered-call example: with shares at $22.18 and the Feb 2026 $22.50 call bid at $0.50, a covered-call seller would realize a 3.70% total return if assigned, with the premium alone representing a 2.25% boost (12.86% annualized YieldBoost). The contract is ~1% out-of-the-money, implied volatility is 78% versus a 12‑month trailing volatility of 63%, and the analytics estimate a 45% probability the option will expire worthless; the write-up notes the trade caps upside if the stock rallies and advises reviewing trading history and fundamentals.

Analysis

Market structure: The RCUS covered‑call example benefits income‑oriented retail and institutional option sellers (collecting a 2.25% one‑year premium = 12.86% annualized) and brokers (commissions); it penalizes long‑only holders if shares rally beyond $22.50. Elevated implied volatility (78% vs 63% realized) signals demand for downside/hedge protection and a willingness to pay for optionality around biotech binary catalysts. Liquidity is concentrated in single‑name equity options; large moves would feed into equity‑volatility products and small‑cap biotech ETFs (XBI) flows, with limited direct FX or IG bond impact absent macro shock.

Risk assessment: Tail risks are classic biotech binaries — clinical failure, FDA rejection, or dilutive secondary offerings — each capable of 30–70% price moves; repo/borrow stress could spike option costs and force adjustments. Near term (days–months) option premiums and assignment risk dominate; medium term (6–12 months) trial/readout/capital raise outcomes decide direction; long term depends on commercial partnerships and cash runway. Hidden dependencies: open interest, borrow cost, early assignment before catalysts, and dealer gamma; catalyst leaks or a secondary could compress or explode IV.

Trade implications: For neutral‑to‑mildly‑bullish exposure, covered calls (buy RCUS ~22.18 + sell Feb‑2026 $22.50 for $0.50) offer asymmetric income — 3.7% capped upside to strike + 2.25% premium; exit if price > $24.50 or IV declines >15 pts. If seeking pure volatility sell, prefer defined‑risk short call spreads (sell 22.5 / buy 25) or cash‑secured puts (sell Feb‑2026 $20 put if premium ≥ $0.40) rather than naked short calls. Reduce long exposure or hedge ahead of any announced readouts or secondary filings within 30–90 days.

Contrarian angles: The market may be overpricing IV relative to realized vol absent an imminent binary — favor being a net option seller with defined risk rather than option buyer. Conversely, if a clinical readout is imminent or a secondary is likely, IV could rise further making short‑vol trades dangerous; historical small‑cap biotech pre‑readout moves often exceed +100% or −50% in weeks. Unintended consequence: crowded covered‑call positions can lead to mass assignment and volatile rehypothecation if a positive catalyst pushes price just above strikes.

Key Decisions for Investors

• Consider establishing a 1–3% long position in RCUS (ticker RCUS) at or below $22.25 and sell the Feb‑2026 $22.50 call for ~$0.50 (covered call). Target: 3.7% gross to strike + 2.25% premium; close if RCUS > $24.50 or if IV falls by >15 percentage points.
• If willing to own at a lower basis, sell a cash‑secured Feb‑2026 $20 put only if premium ≥ $0.40 (implies ≥2% credit); size to 1–2% of portfolio and be prepared to take assignment at $20 (max effective purchase price $19.60).
• For defined‑risk volatility selling, execute a Feb‑2026 short call spread 22.5/25 for net credit ≥ $0.30 (caps upside and limits loss), size <=2% of portfolio and delta‑hedge weekly until major catalysts pass.
• Avoid adding >5% outright long biotech exposure ahead of any RCUS‑filed secondary or clinical readout; if a secondary or readout is filed/announced within 60 days, reduce RCUS exposure by 50% or hedge with long OTM calls (buy Feb‑2026 $27 calls) sized at 10–15% of the underlying position to cap tail risk.